The Medicines and Healthcare products Regulatory Agency (MHRA) has launched a new consultation on proposals to grant indefinite recognition of CE-marked medical devices in Great Britain. For patients, including families within the African diaspora in the UK, this move promises continuity in access to essential medical technologies, reinforcing trust in the healthcare system.
Currently, around 90 percent of medical devices used in Great Britain carry the CE mark, indicating conformity with European standards. The indefinite recognition proposals aim to maintain this supply, protecting patients from interruptions while supporting healthcare providers who rely on these devices every day. This consultation builds on transitional arrangements introduced in 2023 and forms part of the MHRA’s broader strategy to reform medical device regulation in a way that is patient-focused, risk-proportionate, and innovation-friendly.
The proposals focus on three areas: extending transitional arrangements for devices certified under the EU Medical Device Directive, aligning Great Britain’s timelines with the EU’s shift to the Medical Device Regulation; indefinite recognition of devices compliant with the EU MDR and IVDR to reduce supply disruption; and the creation of an international reliance route for higher-risk CE-marked devices to ensure oversight while maintaining patient access. For diaspora communities, many of whom maintain family and medical ties across borders, these measures are significant. They ensure that patients in the UK continue to benefit from devices that are widely trusted across Europe without delays, shortages, or additional costs.
Lawrence Tallon, Chief Executive of the MHRA, highlighted the importance of certainty for both patients and the medical technology sector. He explained that the consultation responds directly to industry feedback, seeking to balance patient safety with innovation. UKCA will be repositioned as a specialist pathway for first-in-market innovative products, including AI-driven medical devices, reflecting the UK’s ambitions to remain a global leader in MedTech.
This approach also aligns with wider government policies for manufactured goods, maintaining consistent recognition of CE-marked products across sectors while strengthening post-market surveillance and improving collaboration with EU regulatory partners. For diaspora families, this reassures that devices approved in Europe will continue to be available in the UK, supporting access to quality care for conditions ranging from chronic illness management to cutting-edge diagnostic technology.
The MHRA is inviting feedback from medical device manufacturers, healthcare professionals, patient groups, and the public to ensure that the proposals reflect patient needs and support the health system effectively. This consultation is open from 16 February to 10 April 2026, giving stakeholders an opportunity to shape the regulatory framework that will underpin UK healthcare access for years to come.
For diaspora communities who rely on the UK healthcare system while maintaining close ties to families across Africa, these proposals are more than administrative changes—they are a safeguard of continuity, trust, and access to life-saving medical technologies. By ensuring the indefinite recognition of CE-marked devices, the MHRA is taking a step that protects both innovation and patient care, reinforcing the UK’s commitment to a health system that works for all, including families navigating the unique challenges of the diaspora experience.
This initiative also complements the Life Sciences Sector Plan and the 10-Year Health Plan, promoting growth, innovation, and patient access while reinforcing the UK’s position as a hub for advanced medical technology. For African diaspora patients and professionals in healthcare and technology, the consultation signals opportunities for engagement, investment, and collaboration in a system designed to be resilient, safe, and forward-looking.
